Monitor for any actual drawdowns under the ELOC, which would increase dilution pressure on the stock. Also watch for any regulatory progress on nicotine or vitamin strips, as that could provide upside catalyst. The stock is likely to remain under pressure due to the dilutive overhang and weak financial position.
Executive Summary
CTT Pharmaceutical Holdings filed Amendment No. 4 to its S-1 registration statement, registering 6,250,000 shares for resale by RH2 Equity Partners under an Equity Line of Credit (ELOC) agreement. The company is a development-stage pharmaceutical firm with no revenue, a history of losses, a going-concern qualification, and only $7,089 cash on hand. The ELOC provides up to $10 million in potential funding, but at the current $0.08 stock price, full issuance would yield only ~$500,000, and the company plans to limit draws to $1 million unless the stock exceeds $1. The filing continues the dilution risk for existing shareholders.
Key Facts
- Development-stage pharmaceutical company with no revenue for the past two years; net losses of $250,229 in FY2024, $155,907 in FY2025, and $84,674 in Q1 2026.
- Auditors include a going-concern qualification; cash balance of $7,089 as of March 31, 2026.
- ELOC with RH2 Equity Partners provides up to $10 million; 6,250,000 shares registered for resale at a 15% discount to VWAP; at current $0.08 price, full issuance yields ~$500,000.
- Company plans to limit ELOC draws to $1 million unless stock price exceeds $1; intends to use proceeds for manufacturing equipment and working capital.
- Management and directors beneficially own approximately 51% of outstanding common stock.
Financial Impact
Dilution of up to 10.4% of outstanding shares from the registered offering; actual dilution depends on drawdown amounts and stock price. No revenue generated; losses continuing.
Risk Factors
- Significant dilution risk from ELOC draws at depressed stock prices.
- Going-concern risk; company may require additional financing beyond the ELOC.
- No near-term revenue visibility; regulatory and commercial milestones uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001171520-26-000162 |
| Exhibit: ex23-1.htm | 0001171520-26-000162 |
| Document: 0001171520-26-000162-index-headers.html | 0001171520-26-000162 |
| Document: 0001171520-26-000162-index.html | 0001171520-26-000162 |
| Document: 0001171520-26-000162.txt | 0001171520-26-000162 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0570 (+0.71%) |
Oct 7, 2026 19d ago | 8-K | $0.0566 | awaiting T+60 | — | $0.0570 (−0.71%) |
Aug 12, 2026 10w ago | 8-K | $0.0660 | awaiting T+60 | — | $0.0570 (−13.64%) |
Jul 24, 2026 13w ago | S-1/A | $0.0660 $0.0589 | ▲ +10.76% | ▲ +14.31% | $0.0570 (+13.64%) |
Jun 29, 2026 17w ago | S-1/A | $0.0750 $0.0485 | ▲ +35.33% | ▲ +38.38% | $0.0570 (+24.00%) |
Jun 16, 2026 18w ago | S-1/A | $0.0800 $0.0518 | ▲ +35.25% | ▲ +38.66% | $0.0570 (+28.75%) |
May 29, 2026 21w ago | S-1/A | $0.0720 $0.0570 | ▲ +20.83% | ▲ +22.02% | $0.0570 (+20.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers